TGFβ - A role in systemic sclerosis?

Journal of Pathology

Volumn 184, Issue 1, 1998, Pages 4-6

  Cotton, Shirley A ^a   Herrick, Ariane L ^b   Jayson, Malcolm I V ^b   Freemont, Anthony J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

Fibroblasts; Fibrosis; Systemic sclerosis; Transforming growth factor beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

CELL ACTIVATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMIC SCLEROSIS;

CELL CULTURE TECHNIQUES; FIBROBLASTS; HUMANS; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031886420     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0     Document Type: Short Survey

References (25)

1. Taipale J, Miyazana K, Heldin C-H, Keski-Oja J. Latent transforming growth factor β ssociates to fibroblast extracellular matrix via latent transforming growth factor β bindinig protein. J Cell Biol 1994; 124: 171-181.
2. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med 1987; 165: 251-256.
3. Moses HL, Coffey RJ, Loef EB, Lyons RM, Keski-Oja J. Transforming growth factor beta regulation of cell proliferation. J Cell Biol 1987; 5(Suppl): 1-7.
4. Varga J, Rosenbloom J, Jimanez SA. Transforming growth factor beta causes persistent increase in steady state expression of type I and type III collagen and fibronectin mRNA in normal human dermal fibroblasts. Biochem J 1987; 247: 597-604.
5. Takehara K, LeRoy EC, Grotendorst GR. Transforming growth factor beta inhibition of endothelial cell proliferation: alteration of EGF binding and EGE induced growth regulator (competence) gene expression. Cell 1987; 49: 415-422.
6. Gruschwitz M, Muller PU, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor beta in skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990; 94: 197-203.
7. Sfikakis PP, McCune B, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC. Immunohistological demonstration of transforming growth factor beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993; 69: 199-204.
8. Sato M, Isikawa O, Miyachi Y. An immunohistochemical study on transforming growth factor beta in the skin of systemic sclerosis patients with reference to the histopathologic stage. Eur J Dermatol 1996; 6: 482-485.
9. Helman S, Cotton SA, Jayson MIV, Hoyland J, Herrick A, Freemont AJ. Microvascular abnormality and TGFβ in systemic sclerosis skin. Br J Rheumatol 1997; 36(Suppl 1): 30(54A).
10. Gabrielli A, Di Loreto C, Taborro R, et al. Immunohistochemical localisation of intracellular and extracellular associated TGFβ in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993; 68: 340-349.
11. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black CM. Immunocytochemical localisation and serological detection of transforming growth factor β1. Arthritis Rheum 1994, 17: 278-288.
12. Perlish JS, Bashey RI, Stephens RE, Fleischmajer R. Connective tissue synthesis by cultured scleroderma fibroblasts. Arthritis Rheum 1976; 19: 891-901.
13. Uitto J, Bauer EA, Eisen AZ. Scleroderma: increased biosynthesis of triple helical type I and type III pro-collagens associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 1979; 64: 921-930.
14. Inagaki Y, Truter S, Ramirez F. Transforming growth factor beta stimulates alpha 2(I) collagen gene expression through cis-acting element that contains an SP1 binding site. J Cell Biol 1994; 269: 14828-14834.
15. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 281-284.
16. Kukuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K. Serum tissue inhibitor of metalloproteinase in patients with systemic sclerosis. J Am Acad Dermatol 1995; 973-978.
17. Ichiki Y, Smith EA, LeRoy EC, Trojanowska M. Basic fibroblast growth factor inhibits basal and transforming growth factor β induced collagen α2(I) gene expression in scleroderma and normal fibroblasts. J Rheumatol 1997; 24: 90-95.
18. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of PDGFα receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175: 1227-1234.
19. 7 but not by TGFβ. J Invest Dermatol 1992; 98: 86-91.
20. Clark RAF, Nielsen LD, McPherson JM. Collagen matrices depress unstimulated and TGFβ stimulated fibroblast synthesis of collagen. J Cell Biol 1987; 105: 212A.
21. Kahleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979; 149: 1326-1335.
22. Cotton SA, Jayson MIV, Hoyland J, Herrick A, Freemont AJ. Altered vascular response in systemic sclerosis skin. Br J Rheumatol 1997; 36(Suppl 1): 30(53A).
23. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MIV, Brenchley PEC. Plasma TGFβ in systemic sclerosis: a cross sectional study. Ann Rheum Dis 1994; 53: 763-767.
24. Kahaleh MB, Osborn R, LeRoy EC. Elevated levels of circulating platelet aggregates and beta thromboglobulin in scleroderma. Ann Intern Mad 1982; 96: 610-613.
25. Herrick AL, Illingworth K, Blann A, Hay CRM, Hollis S, Jayson MIV. Von Willebrand factor, thrombomodulin. thromboxane, β thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 55: 122-127.